Mind Over Memory: New Treatment Options for Alzheimer Disease
Credits: 0.50 AMA PRA Category 1 Credits\u2122, 0.50 ABIM MOC or 0.48 AANP, including 0.48 AANP Pharm\xa0CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/mind-over-memory-2\xa0Overview: Embark on a captivating journey with our distinguished neurology faculty as they delve into the revolutionary world of FDA-approved monoclonal antibody therapies targeting \u03b2-amyloid in the treatment of Alzheimer disease (AD). Uncover clinical efficacy, safety nuances, and differences between these newer disease-modifying agents compared to older medications used for AD. Gain insights on identifying which patients are most likely to benefit from these cutting-edge agents and who warrants referral to a dementia specialist. Elevate your understanding of AD treatment and join the forefront of medical innovation.\xa0\xa0Guest: Daniel Press, MD